Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyell Immunopharma (LYEL) Cash from Financing Activities (2020 - 2025)

Lyell Immunopharma's Cash from Financing Activities history spans 6 years, with the latest figure at $50.0 million for Q3 2025.

  • For Q3 2025, Cash from Financing Activities changed N/A year-over-year to $50.0 million; the TTM value through Sep 2025 reached $50.6 million, up 2971.66%, while the annual FY2024 figure was $1.3 million, 23.92% down from the prior year.
  • Cash from Financing Activities for Q3 2025 was $50.0 million at Lyell Immunopharma, up from $183000.0 in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $393.5 million in Q2 2021 and bottomed at -$531000.0 in Q3 2021.
  • The 5-year median for Cash from Financing Activities is $862500.0 (2022), against an average of $25.8 million.
  • The largest YoY upside for Cash from Financing Activities was 2089.05% in 2021 against a maximum downside of 1617.14% in 2021.
  • A 5-year view of Cash from Financing Activities shows it stood at $7.4 million in 2021, then crashed by 88.34% to $863000.0 in 2022, then fell by 12.05% to $759000.0 in 2023, then crashed by 42.42% to $437000.0 in 2024, then soared by 11341.65% to $50.0 million in 2025.
  • Per Business Quant, the three most recent readings for LYEL's Cash from Financing Activities are $50.0 million (Q3 2025), $183000.0 (Q2 2025), and $1000.0 (Q1 2025).